03:00 Mon 29 Jul 2019
Avacta Group PLC - Avacta's CEO to Present at Biotech Investor Day
("
Alastair's presentation will discuss the Company's drug development pipeline based on the combination of Affimer immunotherapies with tumour targeted chemotherapy aimed at addressing the lack of a durable response to current immunotherapies experienced by most cancer patients.
The presentation will be made available on the Company's website: https://www.avacta.com/investors/documents.
- Ends -
For further information from
|
Tel: +44 (0) 844 414 0452 |
|
finnCap Ltd (Nominated Adviser and Joint Broker)
|
Tel: +44 (0) 207 220 0500
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217
|
|
Turner Pope Investments
Yellow Jersey PR (Financial Media and IR)
|
Tel: +44 (0) 203 621 4120
Tel: +44 (0)7764 947 137 Tel: +44 (0)7544 275 882
Tel: +44 (0)7787 502 947 |
About
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of
By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
About the European Biotech Investor Day
The European Biotech Investor Day in NYC, features privately-held and EU-listed biotechnology companies representing the "Next Wave of Opportunities" emerging from
Participating companies offer compelling or novel approaches to addressing a range of indications. To inquire about Solebury Trout or to attend the event, please contact
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE